The results showed obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at week 44.

The study is said to be the first to demonstrate efficacy for FcRn inhibition in SLE.

On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical ...

TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use ...

The Phase II study was conducted in France, Germany, Italy and the UK in pwCF.

Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary ...

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular dystrophy, did not achieve its primary endpoint, according to findings published in ...

BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab ...

Please provide your email address to receive an email when new articles are posted on . The primary endpoint was not met in either study, which combined sozinibercept (Opthea) with ranibizumab or ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...